


## PDAC-on-chip for *in vitro* modeling of stromal and pancreatic cancer cells crosstalk


Viola Sgarminato<sup>a,b</sup>, Simone Luigi Marasso<sup>c,d</sup>, Matteo Cocuzza<sup>c,d,e</sup>, Giorgio Scordo<sup>c,‡</sup>, Alberto Ballezio<sup>c</sup>, Gianluca Ciardelli<sup>a,e,f</sup>, Chiara Tonda-Turo<sup>a,e,\*</sup>

### SUPPLEMENTARY INFORMATION

#### CellTiter-Blue Cell Viability Assay



**Fig. S1** Viability assay to identify the appropriate concentration of Fetal Bovine Serum (FBS) in the co-culture medium. The bar graph shows the fluorescence intensity measured for HFF1 cultured in DMEM (HFF1\_DMEM) and in DMEM/F-12 supplemented with 10% FBS (HFF1\_F12 10%) or 15% FBS (HFF1\_F12 15%) and for HPDE-KRAS cultured in RPMI (HPDE-KRAS\_RPMI) and in DMEM/F-12 supplemented with 10% FBS (HPDE-KRAS\_F12 10%) or 15% FBS (HPDE-KRAS\_F12 15%). Tukey's multiple comparisons test: \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .



**Fig. S2** Images from Scanning Electron Microscopy (SEM) analyses at different magnifications showing the PCL/Gel nanofibrous membrane architecture. Scale bars 5  $\mu\text{m}$ .




Fig. S3 Change in HFF1 aspect ratio under co-culture with HPDE-KRAS cells. Elongated fibroblasts show a mean aspect ratio above 3.9 while the round shape of HFF1 is reflected by an aspect ratio  $\sim 2$ . Tukey's multiple comparisons test: \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ . 60 cells in three images per condition ( $n=3$ ) were analyzed. Representative images are reported in Fig.2 (first row).





Fig. S4 Activation of human fibroblasts upon culture with HPDE-KRAS supernatant. (a-d) Fluorescent images of HFF1 embedded in type I collagen hydrogel and stained with Alexa Fluor™ 488 Phalloidin (F-actin) and DAPI (nuclei) to highlight the differences between the fibroblasts' cytoskeletons before (a-b) and after (c-d) the incubation with tumor supernatant. Cells were grown for 48h before the staining. Scale bars 20  $\mu\text{m}$ .



**Fig. S5** Activation of human fibroblasts upon culture with HPDE-KRAS supernatant. (a-b) Confocal images showing the expression of  $\alpha$ -SMA by fibroblasts embedded in type I collagen hydrogel (a) and seeded in the bottom layer of the microfluidic device (b) before (i-iii) and after (iv-vi) the treatment with HPDE-KRAS supernatant. The plots (a<sub>iii,vi</sub>-b<sub>iii,vi</sub>) report the intensity values along the two lines drawn in the images a<sub>ii,v</sub> and b<sub>ii,v</sub> (vertical line=1; horizontal line=2). Scale bars 100  $\mu$ m. (c) IL-6 cytokines concentration in supernatants collected from the bottom chamber of the microfluidic device where the fibroblasts were cultured for 48h with (Treated) and without (Untreated) the HPDE\_KRAS-derived supernatant. Bar plots of the data obtained from ELISA test IL-6 analysis for each culture condition (n=2). Tukey's multiple comparisons test: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.